Company / FCF Margin
Denali Therapeutics Inc. FCF Margin History
FY2020-FY2023 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest FCF Margin
-112.2%
FY2023
5-year range
-635.3% / 123.1%
FY2020-FY2023
Trend
-191.2%
vs FY2022
Sector context
#94 of 133
Health Care
What the data says
At -112.2%, Denali Therapeutics Inc.'s fcf margin ranks #94 of 133 in the Health Care sector. Improved from -635.3% to -112.2% over the past 2 years.
Based on SEC 10-K filings.
-112.2% in FY2023 with a 3-year CAGR of -148.4%.
Improved from -635.3% to -112.2% over the past 2 years.
Health Care sector context is included.
FCF Margin over time
Growth rates
- 3-Year Change
- -148.4pp
- 5-Year Change
- -
- 10-Year Change
- -
Sector benchmark
#94 of 133 in Health CareTop 71% of 133This company -112.2% Sector average -632.8%
▼
+82.3% above sector average
Key checks
Key Insights
- In FY2023, fcf margin decreased 191.2% year-over-year.
- Currently 520.6pp above the Health Care sector average.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 0.73 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | FCF MarginValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | - | - |
| FY2024 | - | - |
| FY2023 | -112.2% | -191.2% |
| FY2022 | 123.1% | +119.4% |
| FY2021 | -635.3% | -1856.5% |
| FY2020 | 36.2% | - |
| FY2019 | - | - |
| FY2018 | - | - |
| FY2017 | - | - |
| FY2016 | - | - |
As of FY2023 · SEC 10-K · Updated Jun 30, 2026